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Abstract
The 2013 update of the American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP)
human epidermal growth factor receptor 2 (HER2) testing guidelines recommend using an alternative
chromosome 17 probe assay to resolve HER2 results determined to be equivocal by immunohistochemistry
(IHC) or fluorescence in-situ hybridization (FISH). However, it is unclear if cases considered HER2-positive
(HER2+) by the alternative probe method are similar to those classified as HER2+ by traditional IHC and
FISH criteria and benefit the same from HER2-targeted therapies. We studied the clinical and pathologic
features of all 31 breast cancers classified as HER2+ by the alternative probe method at our institution since
2013 and determined their PAM50 intrinsic molecular subtypes. For comparison, we analyzed 19
consecutive cases that were classified as HER2+ by traditional FISH criteria during the same time period.
Thirty (97%) cancers in the alternative probe cohort were estrogen receptor (ER)-positive (ER+), while only
9/19 (47%) of traditional HER2 controls were ER+ (p = 0.0002). Sufficient tissue for intrinsic subtype analysis
was available for 20/31 cancers in the alternative probe cohort and 9/19 in the traditional HER2+ group.
None (0%) of the 20 alternative probe-positive cases were of the HER2-enriched intrinsic subtype, while 8/9
(89%) of those HER2+ by traditional FISH criteria were HER2-enriched (p = 0.0001). These findings suggest
that breast cancers classified as HER2+ only by the alternative probe method are biologically distinct from
those classified as HER2+ by traditional criteria, and raises questions as to whether or not they derive the
same benefit from HER2-targeted therapies.
Keywords: HER2-positive breast cancer, PAM50 intrinsic subtype, HER2 alternative probe, ASCO-CAP
guidelines
Approximately 15% of breast cancers are classified
as human epidermal growth factor receptor 2
(HER2)-positive (HER2+) [1]. HER2 positivity confers
an aggressive phenotype and was associated with
poor long-term outcomes [2] until the incorporation
of HER2-targeted agents into treatment which re-
sulted in a 50% reduction in recurrence and a 30%
improvement in survival [3, 4].
The two most common methods for HER2 testing
are immunohistochemistry (IHC) to assess protein
overexpression and fluorescence in-situ hybridization
(FISH) to assess gene amplification. Single-probe
FISH enumerates HER2 copies per nucleus.
Dual-probe FISH includes both an HER2 probe and
a chromosome 17 centromere probe, providing an
HER2/CEP17 ratio in addition to absolute HER2
copy number [5]. Intrinsic molecular subtype ana-
lysis using gene expression profiling is not used clin-
ically, but may better represent the inherent biologic
heterogeneity of breast cancer than conventional bio-
markers such as estrogen receptor (ER), progesterone
receptor (PR), and HER2 [6, 7]. While all intrinsic
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molecular subtypes have been observed among clin-
ically HER2+ breast cancers defined by traditional
IHC/FISH criteria, the majority (67%) are classified
as HER2-enriched, with ER-positive (ER+)/HER2+
cases being HER2-enriched 54% of the time [8]. In
contrast, among clinically HER2-negative (HER2–)
cases, only ~ 7% are of the HER2-enriched subtype
[9]. Recent data suggest that the HER2-enriched mo-
lecular subtype may be a better predictor of re-
sponse to HER2-targeted therapy than IHC or FISH
assessments [10].
The American Society of Clinical Oncology (ASCO)
and College of American Pathologists (CAP) updated
their HER2 testing guidelines in 2013 [11]. It is now
recommended that for HER2 equivocal cases (i.e.,
IHC 2+ or HER2 copies ≥ 4 and < 6 and HER2/CEP17
ratio < 2), FISH be performed using a probe for other
genes on chromosome 17 to serve as the denomin-
ator to determine the HER2/chromosome 17 ratio.
Genes such as retinoic acid receptor alpha (RARA),
Smith-Magenis Syndrome (SMS), or tumor protein
p53 (TP53) are located further away from HER2 than
the centromere and are thus less likely to be
co-amplified with HER2 than the centromere. Thus,
an HER2/alternative chromosome 17 probe ratio of ≥
2 may more accurately reflect HER2 gene amplifica-
tion than the HER2/CEP17 ratio [12].
Using the alternative probe method has resulted in an
increased number of breast cancers classified as
HER2-positive [13]. However, whether or not these can-
cers have similar clinical and pathologic features or re-
spond as well to HER2-targeted therapy as breast cancers
defined as HER2-positive by traditional IHC/FISH criteria
is unclear.
We identified all breast cancers at our institution
since 2013 classified as HER2-positive only by the al-
ternative probe method. We identified 31 such cases,
and 20 of those had sufficient tissue for PAM50 in-
trinsic subtype analysis. As a comparison group, we
selected 19 consecutive cases classified as HER2+ by
traditional FISH criteria during the same period. We
reviewed their clinical and pathologic features and de-
termined intrinsic molecular subtype analysis using
the PAM50 research-based assay as previously de-
scribed [14] (Tables 1 and 2).
Among the 31, alternative probe-positive cases, 30
(97%) were ER+ and 11 (35%) were high grade. In con-
trast, among the 19 cases that were HER2+ by traditional
FISH criteria, nine (47%) were ER+ and 14 (74%) were
high grade (p = 0.0002). Repeat HER2 testing was per-
formed on a second tumor sample in 11 cases and seven
of those were negative for HER2 gene amplification by
both traditional FISH criteria and alternative probe
method. Two cases were confirmed HER2+ by
conventional FISH and two only by the alternative probe
method (Tables 1 and 2).
Adequate tissue for PAM50 intrinsic subtype ana-
lysis was available for 20 alternative probe-positive
cases and nine cases that were HER2+ by traditional
FISH criteria. None (0%) of the 20 alternative probe
cancers had HER2-enriched intrinsic subtype, while
eight (89%) of the nine HER2+ traditional controls
were of the HER2-enriched molecular subtype (p =
0.0001).
Clinical and pathologic data for patients in the al-
ternative probe-positive cohort is provided in Table 1.
Staging information was available for 24 patients.
Twenty-one had early-stage disease (12 = node nega-
tive, 9 = node positive), one patient had a postmas-
tectomy recurrence, and two patients had metastatic
disease. Treatment information was available for 22
patients. Only four patients did not receive
HER2-targeted therapy, one with metastatic disease
and three with node-negative early-stage disease. Of
the early stage patients who did receive
HER2-targeted therapy, only two received it in the
neoadjuvant setting, along with chemotherapy; one
had a pathologic complete response (pCR) and one
had partial responses (PR). Similarly, only four pa-
tients in the traditional HER2+ cohort received neo-
adjuvant HER2-targeted therapy with chemotherapy;
two had a pathologic PR and two (both patients with
HER2-enriched subtype) achieved pCR (Table 2).
Given the small number of patients treated in the
neoadjuvant setting, we cannot draw meaningful
conclusions regarding response to HER2-targeted
therapy among the alternative probe cases.
In the alternative probe-positive cohort, when
considering the early-stage patients who received concur-
rent chemotherapy and HER2-targeted therapy, all except
one had ER+ tumors, eight had no nodal involvement, and
five had only N1a or N1mic disease. Had these tumors
been considered HER2-negative, all might have been can-
didates for genomic expression assays to determine the
need for chemotherapy, yet only three were evaluated for
such (Table 1). Oncotype Dx was performed on tumors
from three patients, with recurrence scores of 29, 26, and
12. The patient with the recurrence score of 12 had
T1cN0 ER+ disease, was treated with endocrine therapy
only without any chemotherapy or HER2-targeted ther-
apy, and remains in remission at the last follow-up.
In conclusion, these findings highlight the unique
pathologic and molecular characteristics of breast can-
cers classified as HER2+ only by an alternative probe
method, and raise questions regarding the appropriate
management of these cancers. More data regarding re-
sponse of these breast cancers to HER2-targeted therap-
ies is needed.
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Table 2 Randomly selected consecutive HER2+ cases by traditional FISH criteria
Patient
no.
Histology Grade ER/
PR
HER2
IHCa
HER2
copies
HER2/
CEP17
ratio
Intrinsic
subtype
TNM
stage
Herceptin ±
chemo
given?
NAT,
AT,
MET
Herceptin ±
chemo
regimenb
If NAT,
pathologic
response?
Follow-
up
timec
Disease
status
1 IDC 3 +/+ + 3 19.1 5.8 NS pT1cN0 No; patient
declined
N/A N/A N/A 9
months
Remission
2 IMPC 2 −/− + 3 17.6 4.8 NS pT1bNx No; not
offered 2/2
age/
comorbidities
N/A N/A N/A 4
months
Died of
AAA
rupture
3 IDC 3 +/+ + 3 20.6 6.6 Luminal
A
cT2N1M0 Yes NAT
& AT
NAT: T-DM1
+ P on a trial,
AT: THP
PR 25
months
Remission
4 IDC 3 +/+ + 3 > 10 5.2 HER2-E cT1cN0 Yes NAT
& AT
NAT: T-DM1
+ P on a trial,
then AT: do-
cetaxel ×4 cy-
cles + H
×1 year
CR 12
months
Remission
5 IDC 3 −/− + 3 > 20 1.0d HER2-E cT1cN0 Yes NAT THP CR 18
months
Remission
6 IDC 2 −/− + 3 12.8 5.4 NS cT2-3 N1 Yes NAT THP-ddAC PR 5
months
Remission
7 IDC 3 −/− + 3 23.3 5.3 HER2-E cT2N0 na na Na na na na
8 IDC 3 −/− + 3 20.7 6.4 NS pT1cNx Yes AT TH N/A 27
months
Remission
9 ILC 2 −/− + 3 > 6 5.6 NS pT1aN0 Yes AT TH N/A 25
months
Remission
10 IDC 3 −/− + 3 26.3 7.6 HER2-E pT1bN0 Yes AT TH N/A 30
months
Remission
11 IDC 3 −/− + 3 > 10 > 3.8 HER2-E pT1bN0 Yes AT TH N/A 21
months
Remission
12 IMPC 3 −/− + 3 19.85 7.4 HER2-E pT1cN1a Yes AT ddAC-TH N/A 28
months
Remission
13 IDC 2 +/− + 3 37.2 6.8 NS pT1bN0 Yes AT ddAC-TH N/A 26
months
Remission
14 IDC 3 +/− + 3 6.88 3.2 NS pT2N1a Yes AT THP
×12 weeks,
ddACX2
(stopped 2/2
SAE, 1 year
H)
N/A 22
months
Remission
15 IDC 3 +/− + 3 > 20 9.5 NS pT1aN0 Yes AT T-DM1 on a
trial
N/A 20
months
Remission
16 IDC 3 +/− + 3 23 8.1 HER2-E pT1bN1a Yes AT ddAC-THP N/A 17
months
Remission
17 IDC 3 +/+ + 3 > 10 3 NS T2N1M1b Yes MET THP, AC,
various
N/A 35
months
Alive, on
tx
18 IDC 3 −/− + 3 26.7 9.4 HER2-E na na na na na na na
19 IDC 2 +/− + 3 20.3 3.4 NS cT3N1 na na na na na na
aHER2 IHC: 0–1+ is negative, 2+ is equivocal, 3+ is positive
bAll patients who received trastuzumab-based treatment received trastuzumab (H) for 1 year unless otherwise specified
cFollow up time defined as time in months from date of initial breast biopsy to date of last clinical follow-up
d HER2 ratio 1.0 because HER2 copies and CEP 17 copies both > 20, so HER2 alternative probe ratio performed to confirm HER2 status
AC Adriamycin + cyclophosphamide, AT adjuvant therapy, CR complete response, ddAC dose-dense adriamycin + cyclophosphamide, ER
estrogen receptor, FISH fluorescence in-situ hybridization, H herceptin (trastuzumab), HER2 human epidermal growth factor receptor 2, HER2-E
HER2-enriched, IDC invasive ductal cancer, IHC immunohistochemistry, ILC invasive lobular cancer, IMPC invasive micropapillary cancer, MET
therapy for metastatic disease, N/A not applicable, na not available, NAT neoadjuvant therapy, NS not sufficient for testing, P pertuzumab, PR
partial response, PR progesterone receptor, T weekly paclitaxel ×12, T-DM1 ado-trastuzumab, TNM tumor node metastasis, Tx therapy
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